4CMenB tied to modest gonorrhea protection in real-world study

The 38.4% reduction in gonorrhea risk “could translate into preventing a substantial number of infections and complications.”

By
Julia Cipriano, MS, CMPP
September 9, 2026
4 min

MDSpire News

Overview

A study found that the 4CMenB vaccine showed an effectiveness of 38.4% in reducing gonococcal notifications among adolescents in high-prevalence settings.

Background

Gonorrhea is a significant public health concern, particularly among adolescents, due to its potential complications such as pelvic inflammatory disease and infertility. The close genetic relationship between Neisseria gonorrhoeae and Neisseria meningitidis raises interest in the potential for meningococcal vaccines to provide cross-protection against gonorrhea.

Data Highlights

Measure	Value
Vaccine Effectiveness (2 doses)	38.4% (95% CI, 18.6%-53.4%)
Overall Meningococcal Carriage Prevalence	4% to 6.2%
Odds Ratio for Carriage Increase	1.68 (95% CI, 1.14-2.48)
Percentage of Fully Vaccinated Adolescents	9.6%
Percentage Identifying as Aboriginal or Torres Strait Islander	42.4%

Key Findings

The 4CMenB vaccine provides a two-dose effectiveness of 38.4% against gonorrhea.
Vaccinated adolescents had lower gonococcal notifications compared to unvaccinated peers.
Meningococcal carriage increased from 4% to 6.2% post-vaccination.
Carriage of meningococci associated with disease remained stable.
Limitations included lower-than-expected vaccine uptake and missing data in the carriage analysis.